CJC-1295 (NO DAC) + Ipamorelin Peptide Vial Lyophilisate For Lab Research

BATCH NR: NBLCP1007261101

TESTED FOR:

✓IDENTITY (LC-MS)
✓WEIGHT

VIEW LAB REPORTS

Overview

CJC-1295 (No DAC) and Ipamorelin are synthetic peptides studied in endocrine and growth-hormone research. CJC-1295 (No DAC) is a modified GHRH(1–29) analog studied for stimulating endogenous GH release via pituitary GHRH receptor activation, with a shorter half-life than DAC-modified analogs. Ipamorelin is a selective ghrelin receptor (GHS-R1a) agonist studied for GH release with minimal reported activity on prolactin or cortisol pathways in experimental models. The combination is frequently examined in research on synergistic, pulsatile GH release.

Mechanism of Action (as reported in preclinical/limited clinical literature)

CJC-1295 (No DAC)

• Mimics endogenous GHRH
• Binds GHRH receptors in the anterior pituitary
• Stimulates pulsatile GH secretion
• Enhances downstream IGF-1 signaling in experimental models

Ipamorelin

• Selective GHS-R1a agonist
• Stimulates GH release from somatotroph cells
• Minimal observed activity on cortisol/prolactin in studies

Combined (hypothesized, under investigation)

• Complementary activation of GHRH + ghrelin axis
• Enhanced pulsatile GH release patterns
• Increased overall GH secretion magnitude in experimental settings

Research Applications

• Endocrine: GH secretion dynamics, pituitary signaling, GHRH/ghrelin receptor interaction, hormonal pulsatility modeling
• Metabolic: IGF-1 axis regulation, lipid metabolism, glucose homeostasis, energy balance signaling
• Musculoskeletal: muscle protein synthesis pathways (experimental), connective tissue regeneration, bone metabolism
• Aging/Cellular: cellular regeneration pathways, age-related GH decline models, mitochondrial function, tissue repair
• Neuroendocrine: HPA-axis regulation, neurohormonal feedback loops, central regulation of growth signaling

Technical Specifications

Stability & Storage

Lyophilized: Store at -20°C; protect from light/moisture; avoid repeated freeze-thaw. Reconstituted: Store at 2–8°C; sterile handling; stability depends on solvent/conditions.

Pharmacokinetic Notes (Research Data)

CJC-1295 (No DAC) shows extended but non-permanent GHRH receptor activity, shorter half-life than DAC-modified analogs. Ipamorelin shows short systemic half-life, rapid receptor binding, GH release typically pulsatile in experimental models.

Research Use Only — Please Read

FOR RESEARCH USE ONLY. This material is intended exclusively for laboratory research by qualified professionals.

This product:

• Is not approved for human use
• Is not approved for veterinary use
• Is not intended to diagnose, treat, cure, or prevent any disease
• Is not a dietary supplement
• Must not be used in clinical or therapeutic applications

All information reflects published scientific literature and experimental research contexts. Results observed in vitro or animal models may not translate to human physiology.

Scientific Reference

1. Teichman SL et al. Prolonged stimulation of growth hormone and IGF-1 secretion by CJC-1295. Journal of Clinical Endocrinology & Metabolism.
2. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone and GHRH physiology. Endocrine Reviews.
3. Alba M. et al.

   Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse

4. Raun K et al. Ipamorelin: a highly selective growth hormone secretagogue. European Journal of Endocrinology.
5. Smith RG et al. Growth hormone secretagogue receptor research. Endocrine Reviews.

Want to learn more? Read our CJC-1295 and Ipamorelin research article →

CJC-1295 No DAC vs CJC-1295 with DAC→